Unknown OBSERVATIONAL NCT04096547

Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment (XAIENT)

A Prospective, Non-interventional, Multicenter Observational Study to Evaluate the Effectiveness and Safety of Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment

Sponsor: Bayer

Conditions Atrial Fibrillation Elderly Renal Insufficiency Rivaroxaban

Interventions Rivaroxaban

Updated 7 times since 2019 Last updated: Oct 19, 2020 Started: Sep 25, 2019 Primary completion: Feb 28, 2022 Completion: Aug 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04096547, this observational or N/A phase trial focuses on Atrial Fibrillation and Elderly and remains ongoing. Sponsored by Bayer, it has been updated 7 times since 2019, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown
Sep 2024 — Sep 2025 [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2021 — Nov 2022 [monthly]

Recruiting

▶ Show 2 earlier versions

Nov 2020 — Jan 2021 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Oct 2019 — Nov 2020 [monthly]

Not Yet Recruiting

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea